These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 34591356

  • 1. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
    Halle M, Schöbel C, Winzer EB, Bernhardt P, Mueller S, Sieder C, Lecker LSM.
    Eur J Heart Fail; 2021 Dec; 23(12):2073-2082. PubMed ID: 34591356
    [Abstract] [Full Text] [Related]

  • 2. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR, PARALLAX Investigators and Committee members.
    JAMA; 2021 Nov 16; 326(19):1919-1929. PubMed ID: 34783839
    [Abstract] [Full Text] [Related]

  • 3. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study.
    Dos Santos MR, Alves MNN, Jordão CP, Pinto CEN, Correa KTS, de Souza FR, da Fonseca GWP, Tomaz Filho J, Costa M, Pereira RMR, Negrão CE, Barretto ACP.
    Am Heart J; 2021 Sep 16; 239():1-10. PubMed ID: 33992607
    [Abstract] [Full Text] [Related]

  • 4. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
    Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR, AWAKE-H. F. Study Investigators.
    Am J Cardiovasc Drugs; 2021 Mar 16; 21(2):241-254. PubMed ID: 32978755
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S.
    Indian Heart J; 2020 Mar 16; 72(6):535-540. PubMed ID: 33357641
    [Abstract] [Full Text] [Related]

  • 6. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F.
    Eur J Heart Fail; 2021 Jan 16; 23(1):127-135. PubMed ID: 33314487
    [Abstract] [Full Text] [Related]

  • 7. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
    Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD.
    JAMA Cardiol; 2018 Jun 01; 3(6):498-505. PubMed ID: 29617523
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, Okino N, Guo W.
    J Cardiol; 2017 Sep 01; 70(3):225-231. PubMed ID: 28024961
    [Abstract] [Full Text] [Related]

  • 9. Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction.
    Edelmann F, Jaarsma T, Comin-Colet J, Schorr J, Ecochard L, Hussain RI, Piepoli MF.
    Eur J Heart Fail; 2020 Sep 01; 22(9):1724-1733. PubMed ID: 32468672
    [Abstract] [Full Text] [Related]

  • 10. Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Owens RL, Birkeland K, Heywood JT, Steinhubl SR, Dorn J, Grant D, Fombu E, Khandwalla R.
    J Card Fail; 2021 Dec 01; 27(12):1466-1471. PubMed ID: 34428592
    [Abstract] [Full Text] [Related]

  • 11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar 01; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators.
    N Engl J Med; 2019 Feb 07; 380(6):539-548. PubMed ID: 30415601
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS, EVALUATE-HF Investigators*.
    Circ Heart Fail; 2021 Mar 07; 14(3):e007891. PubMed ID: 33663237
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study.
    Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, Desai AS, Ohishi T, Iimori T, Kitamura T, Guo W, PARALLEL-HF Investigators.
    Circ J; 2021 Apr 23; 85(5):584-594. PubMed ID: 33731544
    [Abstract] [Full Text] [Related]

  • 15. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
    Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, Sharma K, Solomon SD, Starling RC, Ward JH, Williamson KM, Zieroth S, Hernandez AF, Mentz RJ, Braunwald E.
    J Am Coll Cardiol; 2024 Mar 26; 83(12):1123-1132. PubMed ID: 38508844
    [Abstract] [Full Text] [Related]

  • 16. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    JAMA Cardiol; 2020 Feb 01; 5(2):202-207. PubMed ID: 31825471
    [Abstract] [Full Text] [Related]

  • 17. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    Myhre PL, Prescott MF, Murphy SP, Fang JC, Mitchell GF, Ward JH, Claggett B, Desai AS, Solomon SD, Januzzi JL.
    JACC Heart Fail; 2022 Feb 01; 10(2):119-128. PubMed ID: 35115085
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB, Shah RU, Bress AP, Nelson RE, Bellows BK.
    JACC Heart Fail; 2016 May 01; 4(5):392-402. PubMed ID: 27039128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.